Logical Biological and Bcell Design announce strategic partnership for engineered disease state materials

Sept. 18, 2025
2 min read

Logical Biological and Bcell Design announced a long-term strategic partnership to deliver engineered disease state materials for diagnostic and research markets. Working together, the two companies will develop customized engineered disease state and ‘spiking’ materials to deliver compelling alternatives to native disease state plasma.

Materials are designed and formulated to bring native disease state plasma-like performance, aligned and customized to customer’s performance and scale requirements. 

Bcell Design is a manufacturer of high-quality, human Fc antibodies using a proprietary platform technology. These antibodies are designed to replicate performance of native disease state plasma and are already used in FDA approved and CE marked platforms by top 10 IVD companies. 

Logical Biological brings deep expertise in sourcing, processing and providing biological specimens and bulk disease state plasma, alongside custom plasma processing and protein purification capabilities through sister company Logical Antigen. The company is already supplying native disease state plasma and customized critical raw materials at scale to the largest QC calibrator and control manufacturers. 

Disease state plasma is a key component for IVD calibrators and controls, assay development and quality control testing. However, human disease state materials can be difficult to reliably and consistently source. To solve this challenge, engineered materials are formulated with Bcell Design’s patented human Fc monoclonal antibodies to mimic disease state plasma. This provides multiple benefits - including reproducibility and long-term supply sustainability - whilst maintaining high performance levels and offering benchmarking against native plasma samples. 

The strategic partnership will focus on IgM and IgG engineered disease state material for challenging to source materials, including Rheumatoid Factor (RF). By the end of 2025, the companies expect to have well characterized products for ToRCH, infectious diseases and other conditions.

Visit Logical Biological for more news

About the Author

Sign up for Medical Laboratory Observer eNewsletters